Found money for IDEC

IDEC Pharmaceuticals Corp. is hoping to generate a 25 percent dividend from its manufacturing facilities, built in anticipation of handling production of its lead compound, IDEC-C2B8.

With the compound in Phase III trials for follicular non-Hodgkin's lymphomas, IDPH won't be running the plant at maximum capacity this year. That left the San Diego company with a window of opportunity to generate short term revenue from the facility. ...